Orthocell Posts 45% Revenue Growth for December 2025 Quarter
MT Newswires Live
Jan 06
Orthocell (ASX:OCC) posted revenue of AU$3.2 million for the quarter ended Dec. 31, 2025, up 45% on the previous corresponding period, according to a Tuesday filing with the Australian bourse.
Revenue for the period also represents a 7% increase over the previous quarter and the seventh consecutive quarter of record revenue, the filing said.
The increase was mainly due to increased market penetration, particularly Australia, as well as initial financial contributions from early Remplir nerve repair product surgical cases in the US, per the filing.
Shares rose past 1% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.